Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin
- PMID: 15758147
- DOI: 10.1124/mol.104.010579
Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin
Abstract
Replicative bypass of many DNA adducts is dependent on the interaction of hREV1 with DNA polymerase zeta and potentially with members of the Y family of DNA polymerases. To examine the role of hREV1 in the development of cisplatin (DDP) resistance, a subline (2008-shREV1-3.3) of the ovarian carcinoma cell line 2008 was isolated in which stable expression of a short hairpin RNA suppressed hREV1 expression to 20% and reduced hREV1 protein level to 43% of that found in the parental cells. The 2008-shREV1-3.3 cells were 1.5-fold more sensitive to the cytotoxic effect of DDP but less sensitive to the mutagenic effect of DDP as evidenced by a 2.6- or 2.7-fold reduction in the ability to induce clones highly resistant to 6-thioguanine or DDP itself, respectively, in the surviving population. Reduction of hREV1 did not alter the initial rate of DDP adduct removal from DNA but did impair both spontaneous and DDP-induced extra-chromosomal homologous recombination, as measured by the recombination-sensitive reporter vector pBHRF. DDP induced an increase in hREV1 protein level. DDP resistance at the population level evolved 2.8-fold more slowly in the 2008-shREV1-3.3 cells than in the parental cells during repeated cycles of drug exposure. The results indicate that hREV1 functions to enhance both cell survival and the generation of drug-resistant variants in the surviving population. DDP up-regulates hREV1, suggesting that it may enhance its own mutagenicity. Most importantly, hREV1 controls the rate of emergence of resistance to DDP at the population level. Thus, hREV1 is an important contributor to DDP-induced genomic instability and the subsequent emergence of resistance.
Similar articles
-
Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells.Mol Pharmacol. 2006 May;69(5):1748-54. doi: 10.1124/mol.105.020446. Epub 2006 Feb 22. Mol Pharmacol. 2006. PMID: 16495473
-
DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.Clin Cancer Res. 2006 Jan 15;12(2):563-8. doi: 10.1158/1078-0432.CCR-05-1380. Clin Cancer Res. 2006. PMID: 16428501
-
Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.Cancer Res. 1994 Jul 1;54(13):3500-5. Cancer Res. 1994. PMID: 8012973
-
The role of DNA mismatch repair in cisplatin mutagenicity.J Inorg Biochem. 1999 Oct;77(1-2):89-93. doi: 10.1016/s0162-0134(99)00134-8. J Inorg Biochem. 1999. PMID: 10626359 Review.
-
The role of microRNA in the response to cisplatin treatment.Biochem Soc Trans. 2012 Aug;40(4):821-5. doi: 10.1042/BST20120055. Biochem Soc Trans. 2012. PMID: 22817741 Review.
Cited by
-
The roles of DNA polymerase ζ and the Y family DNA polymerases in promoting or preventing genome instability.Mutat Res. 2013 Mar-Apr;743-744:97-110. doi: 10.1016/j.mrfmmm.2012.11.002. Epub 2012 Nov 26. Mutat Res. 2013. PMID: 23195997 Free PMC article. Review.
-
Structural basis of Rev1-mediated assembly of a quaternary vertebrate translesion polymerase complex consisting of Rev1, heterodimeric polymerase (Pol) ζ, and Pol κ.J Biol Chem. 2012 Sep 28;287(40):33836-46. doi: 10.1074/jbc.M112.394841. Epub 2012 Aug 2. J Biol Chem. 2012. PMID: 22859295 Free PMC article.
-
Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy.Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20786-91. doi: 10.1073/pnas.1011409107. Epub 2010 Nov 10. Proc Natl Acad Sci U S A. 2010. PMID: 21068376 Free PMC article.
-
Overexpression of Rev1 promotes the development of carcinogen-induced intestinal adenomas via accumulation of point mutation and suppression of apoptosis proportionally to the Rev1 expression level.Carcinogenesis. 2017 May 1;38(5):570-578. doi: 10.1093/carcin/bgw208. Carcinogenesis. 2017. PMID: 28498946 Free PMC article.
-
Eukaryotic translesion polymerases and their roles and regulation in DNA damage tolerance.Microbiol Mol Biol Rev. 2009 Mar;73(1):134-54. doi: 10.1128/MMBR.00034-08. Microbiol Mol Biol Rev. 2009. PMID: 19258535 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical